JGL Group continues its trend of strong growth and consolidation of market positions, achieving total revenues of EUR 156 million in the first half of the year, representing a 22% increase compared to the same period last year. According to preliminary consolidated reports for H1 2025, operating profitability before depreciation, interest, and taxes (EBITDA) reached EUR 31.5 million, with an EBITDA margin of 21.3%, while net profit rose to EUR 30 million, which is a 50% increase over H1 2024. On a last twelve-month basis, EBITDA reached EUR 50.7 million, and the net debt/EBITDA ratio was reduced to 1.3x, a strong indicator of the company’s investment potential.
"We are coming out of a period marked by strong commercial and operational performance, achieving significant market shares in our key markets. These results are encouraging and provide us with additional strength to continue implementing our strategic goals. At the same time, to maintain stable growth and realize new production investments exceeding those in INTEGRA, we face a series of challenges that require focus, agility, and responsible management. Our success is due to the dedication and expertise of our employees, to whom I extend my gratitude for the excellence they demonstrate daily," said Mislav Vučić, CEO of JGL.
On the Croatian market, JGL became the third-largest OTC company by total market share. Six leading OTC brands – Meralys HA, Aqua Maris, Vizol S, Dramina, Reflustat, and FungilacSet – firmly hold leadership positions in their categories. Notably, Reflustat took the number one position in the antacid segment in 2025, while FungilacSet continues to grow its market share in its fast-growing category.
On international markets, the company achieved record sales and market shares, with a significant contribution from the Aknekutan brand, which continues to hold the leading position in overall company sales. JGL thus confirms its status as one of Croatia’s top exporters, with more than 85% of sales coming from exports, strengthening its global presence.
The first half of the year also saw the opening of the Education Center within the JGL Pharma Valley complex in Rijeka – a new platform for professional training of employees in pharmaceutical production. The center is equipped with 12 educational-production stations that accurately simulate key sterile production processes – from sprays and aerosols to drops – allowing both new and current employees to gain hands-on experience without impacting ongoing production.
"I am extremely proud of our people, who are the foundation of JGL Group’s success. Their commitment, knowledge, and teamwork have enabled us to achieve such strong results and confirm our position in both domestic and global markets. In a time of constant challenges and change, our core values – responsibility, respect, unity, and sustainability – make a difference and ensure stable growth. Together, we are building a company that values every individual’s contribution, while continuing to provide added value to our customers and partners," concluded Eva Usmiani Capobianco, President of the Board of Directors.
Compared to the same period last year, JGL hired 73 new employees, bringing the total number of Group employees to 1,402. The company retained its sixth place on the list of most desirable employers in the Croatian manufacturing sector (Alma Career Croatia, MojPosao) and, for the second year in a row, earned the Equal Pay Champion title (Selectio), confirming its commitment to creating an equal and inclusive work environment.
Key Performance Indicators of the JGL Group (as of 30 June 2025):
- Total Revenue: EUR 156 million (+22% vs. H1 2024)
- Operating Revenue: EUR 147.6 million (+17%)
- EBITDA (MAT): EUR 50.7 million
- EBITDA Margin: 21.3%
- Net Profit: EUR 30.1 million (+50%)
- Net Debt/EBITDA (MAT): 1.3x